Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What team?
Sounds fishy to me.
Let me know if you need a place to crash after.
Right on. I'm going on Thursday.
Good thing you sold EVG...
Great day on the golf course today!
CPQ
Finally some GAP action today.
A nun walks into Mother Superior's office and plunks down into a chair.. She lets out a sigh heavy with frustration..
"What troubles you, Sister?" asked the Mother Superior. "I thought this was the day you spent with your family?
"It was," sighed the Sister. "And I went to play golf with my brother. We try to play golf as often as we can. You know I was quite a talented golfer before I devoted my life to Christ.
"I seem to recall that," the Mother Superior agreed. "So, I take it your day of recreation was not relaxing?"
"Far from it," snorted the Sister. "In fact, I even took the Lord's name in vain today!"
"Goodness, Sister!" gasped the Mother Superior, astonished. "You must tell me all about it!"
"Well, we were on the fifth tee ... And this hole is a monster, Mother - 540 yard, Par 5, with a nasty dogleg left and a hidden green
... And I hit the drive of my life. I creamed it. The sweetest swing I ever made.
And it's flying straight and true, right along the wanted line .. And it hits this bird in mid-flight!"
"Oh my!" commiserated the Mother. "How unfortunate! But surely that didn't make you blaspheme, Sister!"
"No, that wasn't it," admitted Sister. "While I was still trying to fathom what had happened, this squirrel runs out of the woods, grabs my ball and runs off down the fairway!"
"Oh, that would have made me blaspheme!" sympathized the Mother.
"But I didn't, Mother!" sobbed the Sister. "And I was so proud of myself! And while I was pondering whether this was a sign from God this hawk swoops out of the sky and grabs the squirrel and flies off, with my ball still clutched in his paws!"
"So that's when you cursed," said the Mother with a knowing smile..
No that wasn't it either," cried the Sister anguished, "because as the hawk started to fly out of sight, the squirrel started struggling, and the hawk dropped him right there on the green, and the ball popped out of his paws and rolled to about 18 inches from the cup!"
Mother Superior sat back in her chair, folded her arms across her chest, fixed the Sister with a baleful stare and said...
"You missed the fuckin' putt, didn't you?
How's it look now? I'll check with Tackler to see if he's around. What about RR ? Are we going to play Camrose?
Eagle Rock or Coloniale ? Could also do Camrose I suppose.
So we'll have 3. I'll have to find out if Tackler can make it.
Crazy world we live in.
We're Headed for a Huge Wipeout in Natural Gas
By Tom Dyson
Natural gas is plummeting...
Last week, natural gas fell to a fresh seven-year low... trading as low as $2.70 per mcf (that's 1,000 cubic feet).
Here's the thing: I just read a transcript of the latest earnings conference call from Chesapeake Energy. Chesapeake is the largest independent natural gas producer in America.
One analyst asked Aubrey McClendon, Chesapeake's CEO, why he ramped up production recently even though gas prices had fallen so far. Normally, you'd expect the opposite. When you can't make a profit, you cut production to the bone.
McClendon said America's natural gas industry will have filled up all available storage by the end of the year. At this point, there'll be "involuntary curtailments." In a few months, the lack of storage will force gas companies to stop pumping gas.
In the meantime, McClendon needs to pump as much gas as he can before the storage caverns fill up. It's like a race to pick up pennies in front of a steamroller.
"We didn't see any reason to take it on the chin for the team," he concluded.
Over the last few years, the gas industry has borrowed billions of dollars and used this money to develop new gas fields. Natural gas companies have built refineries, ports, pipelines, drilling rigs, platforms, and storage tanks.
Even though the industry isn't making any money pumping natural gas at prices below $3 per mcf, it cannot cut production. These companies have to make interest payments and must earn whatever revenue they can get.
In other words, gas prices are falling because the industry keeps producing as much gas as it can, even though there isn't enough demand.
For now, this hasn't been a showstopper. The U.S. has a huge capacity for storing natural gas. The trouble is, the storage is almost full...
When the storage fills to capacity, there's going to be a storm in the natural gas industry. Many companies will be forced to turn off the spigots. Can you imagine what will happen to earnings at these companies? They'll collapse. How will these companies pay the interest on their debts?
This Commodity Is About to Collapse
Try Making These Extraordinary Gains in ExxonMobil
Gas is cheap, it's clean, and it's made in America. Gas has a great future. But until the storage runs out and half the drilling companies go bankrupt, gas prices won't rise. There'll be too much supply.
Shorting overleveraged, high-cost gas producers is the way to profit from this situation. Many of these companies are going bankrupt in the very near future.
Good investing,
Tom
P.S. The EIA is publishing a report on the amount of natural gas storage still left in America. This report comes out in the next few weeks. I'll let you know when they publish it... and what its implications are. Keep reading.
When are we golfing? How about next Friday?
Hi
Here is a news on a company with a promising cancer drug currently in pre-clinical stage with testing going on at the NCI. I'd be interested in opinions from this board, whether they be
-So what?
-Looks interesting.
-Why are you spamming that here?
-etc...
Thanks,
Results from NCI Five-Dose Study of PharmaGap Cancer Drug Expected Late September
OTTAWA, ONTARIO--(Marketwire - Sept. 2, 2009) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") today announced that results are expected in late September from the United States National Cancer Institute (NCI) follow-up study of the company's lead drug GAP-107B8.
Results from the initial NCI single dose study released on August 24 showed greater than 50% effect of GAP-107B8 in reduction of cancer cell growth in 26 of the 57 human cancer cell lines tested. Compelling results were found in all 9 cancer types tested, with very positive results in melanoma, breast, central nervous system, and prostate cancers.
The initial test used a single low dose (10 uM) to evaluate the effect of GAP-107B8 against the 57 cancer cell lines in the test. In specific melanoma, breast, central nervous system, and prostate cancer cell lines, growth inhibition of 100% was observed (announcement of results can be found on the Company's website www.pharmagap.com).
Following these compelling results in the initial one-dose testing protocol, GAP-107B8 was selected for testing by the NCI in the same NCI-60 tumour cell panel using five dose concentrations. This range of doses is intended to further examine the drug's effectiveness in human cancer tumour cells, to allow further characterization of the drug's activity against various cancer types, and to provide insight into its method of action.
The NCI-60 protocol tests a wide variety of cancers, including breast, colorectal, lung, ovarian, kidney, prostate, leukemia and various central nervous system cancers and melanomas.
About The National Cancer Institute
The National Cancer Institute (NCI), located in Bethesda, MD is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI has a mandate to select and screen novel drug compounds that could potentially make a material difference in the "war against cancer". Selection to the NCI screening program is through a competitive application process. Details on the NCI's compound screening program can be found at http://dtp.nci.nih.gov/. More general information on the NCI is found at www.cancer.gov.
About PharmaGap Inc.
PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com.
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
SIO
Seems to have reversed course this morning.
NG play.
SGG
There will be news. Of that I have no doubt.
NCI 5 dose is the big one but that won't be out until October.
Probably other news before then on OHRI phase 2 and MD Bioscience.
Looks pretty solid to me. I don't see it going much lower. Time will tell.
Well they call you a red neck hillbilly on Stockhouse.
If you read, you would have known for more than a month that they were planning on selling.
Where are your bids? .26
I know you only bash when your trying to save a few cents.
You know that's not true. They have enough money to last until 2nd quarter 2010.
Down 40% from the high. Good enough for me.
JAG
IAE
GAP
They'll be done soon... Long before the results of the 5 dose study.
Or just a few selling a lot.
PharmaGap Releases Compelling Results for Gap-107B8 From the U.S. National Cancer Institute
Last Update: 8/24/2009 9:15:28 AM
OTTAWA, ONTARIO, Aug 24, 2009 (Marketwire via COMTEX) -- PharmaGap Inc. (GAP)(PHRG.F) ("PharmaGap" or "the Company") is pleased to announce results from the initial testing of its lead cancer drug GAP-107B8 by the U.S. National Cancer Institute (NCI). The NCI data clearly demonstrates significant inhibition of cancer cell growth at a low drug concentration (10 micronsM) across a wide range of human cancer cell lines that comprise the NCI-60 panel. As currently configured, the NCI-60 panel is comprised of 57 human cancer cell lines derived from 9 different cancers (breast, prostate, renal, ovarian, CNS, colon, lung, melanoma and leukemia).
The Company is very pleased to report that in this test, GAP-107B8 demonstrated greater than 50% inhibition in cancer cell growth in 26 of 57 cell lines (46% of all cell lines), from all 9 cancer types in the panel, indicating the potential for potent effect of this novel drug compound across a broad range of human cancers.
Notably, 7 of 9 melanoma cell lines showed a dramatic effect, with inhibition of cell growth of 58% to 100%, with one melanoma cell line showing 100% inhibition of cell growth plus cell death in 39% of treated cells. In 4 of 6 breast cancer lines, 67% to 100% inhibition of cell growth was seen, and in 3 of 5 CNS cancer cell lines, growth inhibition was 63% to 100%. In 1 of 2 prostate cancer cell lines, growth inhibition was 100%.
Dr. Doug Cowart, an experienced clinical pharmacologist and CEO of Therapeutic Development Consultants in North Potomac, MD and a member of PharmaGap's Clinical Development Group, commented on the results, "The initial data from the NCI is a powerful and compelling independent validation of GAP-107B8's potential for development in the treatment of a wide range of cancers. We are especially pleased that the data were consistent with the Company's previous finding of the compound's efficacy in breast, colon, lung, and prostate cancer cell lines, while also identifying potential new candidate cell lines, such as those derived from melanoma. We look forward to pursuing the study of all of this new data with our colleague on the Clinical Development Group, Dr. Gary Schwartz, Chief of the Melanoma & Sarcoma Service unit at the Memorial Sloan-Kettering Cancer Center in New York."
Results from the NCI-60 screen for GAP-107B8's anti-proliferative effect on ovarian cancer are also consistent with positive data announced by PharmaGap on August 6, 2009 from studies undertaken by Dr. Barbara Vanderhyden at the Ottawa Hospital Research Institute.
As was announced by the Company on August 13, 2009, based upon the very positive anti-proliferative effect of GAP-107B8 on cancer cells in the one-drug dose study, the NCI has informed the Company that it has selected the compound for a "next phase" dose-response study at 5 concentration levels, so as to better characterize the effects of varying drug dose levels on individual types of cancer, a key element in determining the initial cancer target or targets and designing protocols for clinical trials in humans.
About The National Cancer Institute
The National Cancer Institute (NCI), located in Bethesda, MD is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI has a mandate to select and screen novel drug compounds that could potentially make a material difference in the "war against cancer". Selection to the NCI screening program is through a competitive application process. Details on the NCI's compound screening program can be found at http://dtp.nci.nih.gov/ . More general information on the NCI is found at www.cancer.gov .
About PharmaGap Inc.
PharmaGap Inc. (GAP)(PHRG.F), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com .
Note: No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: PharmaGap Inc.
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-9551
bmcinnis@pharmagap.com
www.pharmagap.com
Copyright (C) 2009 Marketwire. All rights reserved.
Got my GAP. Played golf a couple of times last week.
EKO
Good one Fringe.
Developing story here
NCI Phase 1 results
OHRI Phase 2 results
OHRI animal tests
MD Biosciences update
NCI Phase 2 results
And whatever else... News could come out of nowhere.
Going to be golfing in the rain tomorrow. The spring and summer has been pretty crappy so we are due for and warm fall.
Can't make it out this month.